Alternatives to Nevia Bio

Scent-based multi-cancer early detection screening test using AI and bio-detectors.

Precision vaginal microbiome testing and multi-omics for women's health, offering clinically actionable insights and STI testing.

Nucleix is a liquid biopsy company developing early cancer detection solutions using methylation analysis.

Harnessing genetic data for digital insights in rare and germline disorders.

Developing a liquid biopsy blood test for early disease detection and monitoring using epigenetic information.

OCON Healthcare develops and commercializes innovative women's health products based on its patented IUB® (Intra Uterine Ball) platform.

AI-driven platform for faster and more efficient diagnosis of women's health issues.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.

Develops a computational model of the human body for drug discovery and development.

Variantyx is a precision medicine company offering comprehensive genomic testing solutions for rare genetic disorders, reproductive health, and oncology.

Digital physical therapy and recovery platform using everyday sensors for ongoing health diagnostics.

Sight Diagnostics develops rapid, accurate, and convenient diagnostic testing solutions, including a complete blood count analyzer.

AI-powered spatial biology platform for precision medicine and drug development.

Ukko is developing novel food allergy and disorder treatments using advanced immunology and plant science.

Data-driven drug discovery and development company using machine learning and high-throughput biology.

Genoox provides a cloud-based AI platform for genomic data analysis, connecting clinicians and healthcare organizations.

AI-powered platform for profiling cancer biomarkers from digitized biopsy images.

Remote-controlled micro-robots for precise treatment of central nervous system disorders.

Comprehensive whole-genome monitoring for cancer recurrence and progression.